Affordable Access

deepdyve-link
Publisher Website

Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy.

Authors
  • Wang, Jinqiang
  • Sun, Xuanrong
  • Mao, Weiwei
  • Sun, Weilin
  • Tang, Jianbin
  • Sui, Meihua
  • Shen, Youqing
  • Gu, Zhongwei
Type
Published Article
Journal
Advanced Materials
Publisher
Wiley (John Wiley & Sons)
Publication Date
Jul 19, 2013
Volume
25
Issue
27
Pages
3670–3676
Identifiers
DOI: 10.1002/adma.201300929
PMID: 23740675
Source
Medline
Keywords
License
Unknown

Abstract

A prodrug forms nanocapsules responsive to tumor GSH/ROS heterogeneity releasing the parent drug SN38 via thiolysis in the presence of GSH (glutathione) or via enhanced hydrolysis due to ROS (reactive oxygen species)-oxidation of the linker, giving rise to high in vitro cytotoxicity and in vivo anticancer therapeutic activity. The nanocapsules are a suitable size for tumor targeting by means of the EPR effect and have a fixed SN38 loading content of 35 wt%, ideal for translational nanomedicine.

Report this publication

Statistics

Seen <100 times